a public good project by the
Synthesis
Company
of California

© 2026

Paul Bamborough | doi.page

0 works0 citations0 h-index

Paul Bamborough

GlaxoSmithKline (United Kingdom)(GB)Age UK(GB)

Publications by Year

Research Areas

Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Ubiquitin and proteasome pathways, Melanoma and MAPK Pathways, Histone Deacetylase Inhibitors Research

Most-Cited Works

→ Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation(2020)416 cited
→ Comprehensive characterization of the Published Kinase Inhibitor Set(2015)344 cited
→ Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains(2011)334 cited
→ Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains(2013)302 cited
→ Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition(2015)231 cited
→ Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A)(2012)207 cited
→

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease

(2009)

200 cited

→ Fragment-Based Discovery of Bromodomain Inhibitors Part 1: Inhibitor Binding Modes and Implications for Lead Discovery(2011)190 cited

→ The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor(2014)187 cited

→ Fragment-Based Discovery of Bromodomain Inhibitors Part 2: Optimization of Phenylisoxazole Sulfonamides(2011)176 cited